热门资讯> 正文

展望Therapeutics启动公开募股;股价下跌

2026-03-24 05:41

Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants.
The offering may include pre-funded warrants in place of common stock.
The offering size and terms are not yet finalized.
Proceeds will primarily be used for working capital and general corporate purposes.
OTLK shares down nearly 22% post-market.

More on Outlook Therapeutics

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
Seeking Alpha’s Quant Rating on Outlook Therapeutics
Historical earnings data for Outlook Therapeutics
Financial information for Outlook Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。